Chemomab Therapeutics Ltd - ADR logo

CMMB

Chemomab Therapeutics Ltd - ADR

$3.5

Earnings Summary

Revenue
$0Mn
Net Profits
$-5.1Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Chemomab Therapeutics Ltd - ADR’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Chemomab Therapeutics Ltd - ADR has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Chemomab Therapeutics Ltd - ADR’s net profit fell -199.53% since last year same period to $-5.1Mn in the Q1 2022. On a quarterly growth basis, Chemomab Therapeutics Ltd - ADR has generated -1.35% fall in its net profits since last 3-months.

Net Profit Margins:

Chemomab Therapeutics Ltd - ADR’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Chemomab Therapeutics Ltd - ADR has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Chemomab Therapeutics Ltd - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.24
EPS Estimate Current Year
-0.24

Highlights

EPS Estimate Current Quarter:

Chemomab Therapeutics Ltd - ADR’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a -140% fall from last quarter’s estimates.

EPS Estimate Current Year:

Chemomab Therapeutics Ltd - ADR’s earning per share (EPS) estimates for the current year stand at -0.24.

Key Ratios

Key ratios of the Chemomab Therapeutics Ltd - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-0.44
Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.28
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Chemomab Therapeutics Ltd - ADR’s earning per share (EPS) fell -100% since last year same period to -0.44 in the Q1 2022. This indicates that the Chemomab Therapeutics Ltd - ADR has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Chemomab Therapeutics Ltd - ADR’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Chemomab Therapeutics Ltd - ADR’s return on equity (ROE) stands at -0.28.

Dividend Per Share (DPS):

Chemomab Therapeutics Ltd - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.24
-0.44
-83.33%

Company Information

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022.

Organisation
Chemomab Therapeutics Ltd - ADR
Employees
2.02K